Details of the Drug

General Information of Drug (ID: DM67OU4)

• Drug Name: ANAVEX 2-73

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 1	[1]
Cognitive impairment	6D71	Phase 1	[2]
Infantile spasm	8A62.0	Phase 1	[1]
Parkinson disease	8A00.0	Phase 1	[1]
Rett syndrome	LD90.4	Phase 1	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 317.9
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 4
  Hydrogen Bond Donor Count; 1
  Hydrogen Bond Acceptor Count; 2
• Chemical Identifiers:
  Formula: C19H24ClNO
  IUPAC Name: 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine;hydrochloride
  Canonical SMILES: CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3.Cl
  InChI: InChI=1S/C19H23NO.ClH/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17;/h3-12,18H,13-15H2,1-2H3;1H
  InChIKey: FEQOLYDPQKHFTD-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 46932299
  CAS Number: 195615-84-0
  TTD ID: D09AOO
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Agonist	[1]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Agonist	[3]

Molecular Expression Atlas of This Drug

• The Studied Disease: Alzheimer disease
• ICD Disease Classification: 8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M1 (CHRM1)	DTT	CHRM1	5.59E-01	0.19	0.41

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] 2011 Pipeline of Anavex.